Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claritin Sales Grow For Schering-Plough Despite Zyrtec OTC Competition

This article was originally published in The Tan Sheet

Executive Summary

OTC Claritin sales advanced almost 10 percent in Schering-Plough's fiscal 2008 first quarter despite the "aggressive launch" of Johnson & Johnson's OTC Zyrtec, S-P says

You may also be interested in...

Zyrtec Launch Brings Big Boost To Johnson & Johnson, But Competition Grows

Johnson & Johnson's OTC sales jumped 27 percent to $1.6 billion in the firm's first earnings period with allergy medication Zyrtec (cetirizine 5 mg) available over the counter, according to J&J

Schering-Plough Cutbacks Underscore Consumer Business Importance

Schering-Plough will look to the diversity of its business with strong OTC and animal health divisions to help weather a major company restructuring that will cut roughly 5,500 jobs and achieve $1.5 billion in cost savings by 2012

E.l.f. Hoists 2023 Full-Year Sales Guidance As Value Prices Attract New Customers

E.l.f. Beauty’s sales grew 26% to $122.6m in the fiscal 2023 first quarter, leading the Oakland, CA-based firm to increase full-year projections. According to company leadership, e.l.f. is capturing market share at a rapid clip while expanding distribution, notably in pharmacy retail.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts